Brandenburg Vincent, Floege Jürgen
Medizinische Klinik II, Nephrologie und klinische Immunologie, Universitätsklinikum der Rheinisch-Westfälischen Technischen Hochschule Aachen.
Med Klin (Munich). 2006 Mar 22;101 Suppl 1:158-62.
The progression of chronic kidney disease (CKD) is more than just a simple, creeping loss of kidney function finally resulting in end-stage renal disease (ESRD). First, the growing incidence of CKD implies an exploding socioeconomic burden. Second, clear evidence indicates that CKD is associated with an independent massive increase in the patient's cardiovascular risk. Concerning screening and early diagnosis of CKD serum creatinine alone is an inadequate parameter for the evaluation of renal function. Proteinuria is both an indicator of renal damage as well as a progression factor for ongoing loss of renal function. Optimized treatment of arterial hypertension is of outstanding importance in the management of CKD patients, since high blood pressure is directly as well indirectly, via proteinuria, related to progression of CKD. Agents interfering with the renin-angiotensin system have been proven to be especially effective in antiproteinuric treatment and in slowing the progression of CKD. Our current understanding of optimized antihypertensive and antiproteinuric therapy favors a multimodal treatment regimen. Reduction of proteinuria toward levels < 0.5 g per day would be ideal. By this intervention the risk for both ongoing renal function loss as well as the risk of cardiovascular disease can be markedly reduced.
慢性肾脏病(CKD)的进展并非仅仅是肾功能的简单逐渐丧失,最终导致终末期肾病(ESRD)。首先,CKD发病率的不断上升意味着社会经济负担的激增。其次,明确的证据表明,CKD与患者心血管风险的独立大幅增加相关。关于CKD的筛查和早期诊断,仅血清肌酐作为评估肾功能的参数并不充分。蛋白尿既是肾损伤的指标,也是肾功能持续丧失的进展因素。在CKD患者的管理中,优化动脉高血压的治疗至关重要,因为高血压直接或通过蛋白尿间接与CKD的进展相关。已证明干扰肾素-血管紧张素系统的药物在抗蛋白尿治疗和减缓CKD进展方面特别有效。我们目前对优化的抗高血压和抗蛋白尿治疗的理解倾向于采用多模式治疗方案。将蛋白尿水平降至每天<0.5克将是理想的。通过这种干预,可以显著降低肾功能持续丧失的风险以及心血管疾病的风险。